CN104256623A - Composition for conditioning health of patient suffering from hypertension, hyperlipidemia and hyperglycemia, and preparation method and application of composition - Google Patents
Composition for conditioning health of patient suffering from hypertension, hyperlipidemia and hyperglycemia, and preparation method and application of composition Download PDFInfo
- Publication number
- CN104256623A CN104256623A CN201410566521.3A CN201410566521A CN104256623A CN 104256623 A CN104256623 A CN 104256623A CN 201410566521 A CN201410566521 A CN 201410566521A CN 104256623 A CN104256623 A CN 104256623A
- Authority
- CN
- China
- Prior art keywords
- composition
- conditioning
- high patient
- health
- patient health
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 85
- 230000036541 health Effects 0.000 title claims abstract description 52
- 230000003750 conditioning effect Effects 0.000 title claims abstract description 34
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 206010020772 Hypertension Diseases 0.000 title abstract description 15
- 201000001421 hyperglycemia Diseases 0.000 title abstract description 14
- 208000031226 Hyperlipidaemia Diseases 0.000 title abstract 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 32
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 16
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 16
- 239000011718 vitamin C Substances 0.000 claims abstract description 16
- 238000009472 formulation Methods 0.000 claims description 18
- 239000003826 tablet Substances 0.000 claims description 17
- 239000006189 buccal tablet Substances 0.000 claims description 15
- 229940046011 buccal tablet Drugs 0.000 claims description 15
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 15
- 239000007938 effervescent tablet Substances 0.000 claims description 15
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 14
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 13
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 13
- 229920002774 Maltodextrin Polymers 0.000 claims description 13
- 239000005913 Maltodextrin Substances 0.000 claims description 13
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 13
- 235000009508 confectionery Nutrition 0.000 claims description 13
- 239000000314 lubricant Substances 0.000 claims description 13
- 235000011090 malic acid Nutrition 0.000 claims description 13
- 239000001630 malic acid Substances 0.000 claims description 13
- 229940035034 maltodextrin Drugs 0.000 claims description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- 239000000843 powder Substances 0.000 claims description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- 239000002994 raw material Substances 0.000 claims description 10
- 239000008187 granular material Substances 0.000 claims description 9
- 238000005550 wet granulation Methods 0.000 claims description 9
- 235000008935 nutritious Nutrition 0.000 claims description 8
- 235000020985 whole grains Nutrition 0.000 claims description 7
- 229920002472 Starch Polymers 0.000 claims description 6
- 230000001105 regulatory effect Effects 0.000 claims description 6
- 235000019698 starch Nutrition 0.000 claims description 6
- 239000008107 starch Substances 0.000 claims description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 238000004040 coloring Methods 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 239000007921 spray Substances 0.000 claims description 5
- 239000000080 wetting agent Substances 0.000 claims description 5
- 235000003599 food sweetener Nutrition 0.000 claims description 4
- 239000003765 sweetening agent Substances 0.000 claims description 4
- 230000000694 effects Effects 0.000 abstract description 12
- 239000000463 material Substances 0.000 abstract description 2
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 abstract 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 abstract 1
- 229960002173 citrulline Drugs 0.000 abstract 1
- 235000013477 citrulline Nutrition 0.000 abstract 1
- 235000015872 dietary supplement Nutrition 0.000 abstract 1
- 238000005469 granulation Methods 0.000 abstract 1
- 230000003179 granulation Effects 0.000 abstract 1
- 230000006996 mental state Effects 0.000 abstract 1
- 239000000047 product Substances 0.000 abstract 1
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 26
- 239000000686 essence Substances 0.000 description 19
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 244000269722 Thea sinensis Species 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 206010012601 diabetes mellitus Diseases 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 5
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 4
- 229930064664 L-arginine Natural products 0.000 description 4
- 235000014852 L-arginine Nutrition 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- 238000013459 approach Methods 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 2
- 229910052753 mercury Inorganic materials 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000003860 sleep quality Effects 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 241000427159 Achyranthes Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- 244000175448 Citrus madurensis Species 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 206010048554 Endothelial dysfunction Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000208688 Eucommia Species 0.000 description 1
- 244000130270 Fagopyrum tataricum Species 0.000 description 1
- 235000014693 Fagopyrum tataricum Nutrition 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 240000007049 Juglans regia Species 0.000 description 1
- 235000009496 Juglans regia Nutrition 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 208000000501 Lipidoses Diseases 0.000 description 1
- 206010024585 Lipidosis Diseases 0.000 description 1
- 244000241872 Lycium chinense Species 0.000 description 1
- 235000015468 Lycium chinense Nutrition 0.000 description 1
- 244000197580 Poria cocos Species 0.000 description 1
- 235000008599 Poria cocos Nutrition 0.000 description 1
- 244000179560 Prunella vulgaris Species 0.000 description 1
- 240000001949 Taraxacum officinale Species 0.000 description 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 description 1
- 206010047141 Vasodilatation Diseases 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000021329 brown rice Nutrition 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000009101 diabetic angiopathy Diseases 0.000 description 1
- 201000002249 diabetic peripheral angiopathy Diseases 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000008694 endothelial dysfunction Effects 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000003516 hyperlipidaemic effect Effects 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 229940023488 pill Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 235000008113 selfheal Nutrition 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 231100000216 vascular lesion Toxicity 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 235000020234 walnut Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention provides a composition for conditioning the health of a patient suffering from hypertension, hyperlipidemia and hyperglycemia, and a preparation method and application of the composition. The composition for conditioning the health of the patient suffering from hypertension, hyperlipidemia and hyperglycemia comprises 10 to 50 parts by weight of citrulline and 5 to 10 parts by weight of vitamin C. The preparation method for the composition for conditioning the health of the patient suffering from hypertension, hyperlipidemia and hyperglycemia comprises the four steps of material preparation, crushing, granulation and obtaining of a finished product. The composition for conditioning the health of the patient suffering from hypertension, hyperlipidemia and hyperglycemia is applied to the preparation of a nutritional supplement for comprehensively conditioning the health of the patient suffering from hypertension, hyperlipidemia and hyperglycemia. According to the composition for conditioning the health of the patient suffering from hypertension, hyperlipidemia and hyperglycemia, hypertension, hyperlipidemia and hyperglycemia can be effectively lowered, the sleeping quality and mental state of the patient suffering from hypertension, hyperlipidemia and hyperglycemia can be improved, and side effects are avoided.
Description
Technical field
The present invention relates to technical field of functional food, relate to composition and method of making the same and the application of a kind of conditioning three high patient healths particularly.
Background technology
Hypertension, high fat of blood, hyperglycaemia, being commonly called as " three is high ", is also the arch-criminal of cardiovascular and cerebrovascular diseases, and serious harm modern is healthy.The World Health Organization once clearly proposed, and the first line of defence of anti-angiocardiopathy reduces by three high and control three height exactly.
Hypertension refers to that in the circulatory system, blood pressure is higher than normal, and being often referred to systemic arterial blood pressure and increasing, is a kind of common clinical syndrome.Normally being normal lower than 140/90 millimetres of mercury, and be hypertension higher than 160/95 millimetres of mercury.Because it is occurring unconsciously, therefore claim " killer silently ".
High fat of blood refers to blood cholesterol or triglycerides is too high or HDL-C is too low, and modern medicine is referred to as dyslipidemia.It is the principal element causing arteriosclerosis, is the hazards that development occurs cardiovascular and cerebrovascular diseases.Its incidence of occult, does not have clinical symptoms mostly, therefore is called " stealthy killer ".
Hyperglycaemia is that in body blood, glucose content is higher than normal value, and be a self-existent pathological change in body, diseased region is at blood, and lesion nature is dysglycemia.The clinical manifestation of hyperglycaemia, can have dominant symptom, as thirsty in dry, drinking a lot of water, urine are many, become thin, and can be recessive symptoms, without obviously subjective uncomfortable.
General three high crowds often rely on medicine to maintain the normal of self, but the such medicine of long-term taking can produce dependence, once in a short time not drug administration just there will be the symptoms such as dizzy, dizzy or even brain extravasated blood, and the high medicine of long-term taking three can cause certain infringement to other function of health, unfavorable healthy, and price is also higher.
The high side effect of drug therapy three is large, easily produces dependence, and can cause certain infringement to physical function, unfavorable healthy; Health protection tea is main mainly with Chinese herbal medicine greatly, effective but onset is slow; Nutrient powder with various food materials for raw material processes from strand, expensive, need take for a long time and just can take effect.
Product at present for three high crowds also has health protection tea, nutrient powder etc. except medicine, also has the health food occurred with pharmaceutical dosage forms such as tablet, capsule, oral liquids.Patent 201310293879.9 discloses a kind of anti-3-high health care tea and the invention provides a kind of anti-3-high health care tea, it comprises following raw material by weight: yncaria stem with hooks 15-20 part, rhizoma Gastrodiae 20-30 part, Folium Apocyni Veneti 9-12 part, moutan bark 12-18 part, Radix Astragali 15-18 part, selfheal 20-25 part, chrysanthemum 30-40 part, dandelion 25-30 part, root of bidentate achyranthes 20-25 part, bark of eucommia 12-16 part, fruit of Chinese wolfberry 10-15 part, shell of seaear 20-25 part, when drinking tea, 12 taste Chinese medicines used are easy to get, cost is low, its prescription has purging liver-heat, induce sweat loose cold, effect of replenishing vital essence to tonify kidney, and it is easy to use, tea treats good health care effect.Patent 201310351299.0 discloses one and falls 3-high health care nutrient powder, and it comprises ginkgo 8%, duck wheat 20%, oat 10%, Semen sesami nigrum 10%, soya bean 10%, cumquat sheet 10%, brown rice 14%, Poria cocos 10%, walnut 8%; By selection, previous cleaning, screen, de-stone, fine purifiation, cure, grind, the step such as detection is made.Reasonable mixture ratio of the present invention, the health of product is worth, nutritive value is all very high, and effectively reducing blood pressure and regulating blood lipid, hypoglycemic can protect the heart, is very suitable for three high crowds.But the mostly function singleness of health protection tea, nutrient powder, DeGrain and cause and illegally add medicine.
Therefore, in order to solve above-mentioned deficiency of the prior art, the present invention proposes a kind of new solution.
Summary of the invention
In order to solve the aforementioned problems in the prior, the invention provides composition and method of making the same and the application of a kind of conditioning three high patient healths.According to the composition of a kind of conditioning provided by the invention three high patient healths, can effectively reduce hypertension, hyperglycaemia, high fat of blood, and can improve three high patients sleep quality, improve the state of mind, and to have no side effect.
One aspect of the present invention provides the composition of a kind of conditioning three high patient healths, comprises the vitamin C of citrulling that parts by weight are 10-50 part and 5-10 part.
Further, the composition (hereinafter referred to as this composition) of the high patient health of conditioning three provided by the invention also comprises conventional pharmaceutical adjuvants, and described conventional pharmaceutical adjuvants comprises: malic acid, maltodextrin, sweet mellow wine and essence.
Further, described composition is the formulation being easy to take, absorb and carry.
Further, the formulation of described composition is effervescent tablet, buccal tablet, granule, capsule or oral liquid.
Alternatively, the formulation of described composition is effervescent tablet, comprises the component of following parts by weight: the citrulling of 25-30 part, the malic acid of 7-10 part, the vitamin C of 5-10 part, the maltodextrin of 8-12 part, the sweet mellow wine of 10-15 part, the citric acid of 10-15 part, the sodium acid carbonate of 10-15 part, the sweetener of 0.1-0.5 part, the colouring agent of 0.1-1 part, the essence of 0.2 part, the PVP of the lubricant of 0.5 part and 0.5 part.
Alternatively, the formulation of described composition is buccal tablet, comprise the component of following parts by weight: the citrulling of 10-30 part, the malic acid of 10-20 part, the vitamin C of 5-10 part, the maltodextrin of 10-20 part, the sweet mellow wine of 10-20 part, the soluble starch of 20-40 part, the essence of 0.2 part and the dolomol of 0.3-0.7 part.
The present invention provides a kind of preparation method preparing the composition of the high patient health of described conditioning three on the other hand, comprises the following steps:
(1) feeding: take raw material and pharmaceutic adjuvant;
(2) pulverize: the raw material beyond removing protein sugar, essence, lubricant or dolomol and pharmaceutic adjuvant are pulverized for 80-200 order fine powder;
(3) granulate: after described fine powder is mixed, adopt wet granulation, 40-60 DEG C of dry 0.5-1.5 hour, cross the whole grain of 16-20 mesh sieve;
(4) finished product is obtained: added proteins sugar, essence, lubricant or dolomol mix rear compressing tablet, obtain described composition.
Further, described wet granulation is spray PVP, and makes wetting agent with the ethanol of 95%.
Another aspect of the invention provides the application of composition in the nutritious supplementary pharmaceutical preparing the high patient health of comprehensively regulating three of the high patient health of described conditioning three.
According to composition and method of making the same and the application of the high patient health of conditioning three provided by the invention, following beneficial effect can be brought: can effectively reduce hypertension, hyperglycaemia, high fat of blood, and can improve three high patients sleep quality, improve the state of mind, and to have no side effect.
Accompanying drawing explanation
Fig. 1 shows the schematic flow sheet of the preparation method of the composition of the high patient health of conditioning three that the embodiment of the present invention provides.
Detailed description of the invention
Introduce exemplary embodiment of the present invention in detail with reference to the accompanying drawings.There is provided the object of these exemplary embodiments to be to make those of ordinary skill in the art to be expressly understood the present invention, and can the present invention be realized according to description here.The drawings and specific embodiments are not intended to limit the present invention, and scope of the present invention is defined by the following claims.
One aspect of the present invention provides the composition of a kind of conditioning three high patient healths, comprises the vitamin C of citrulling that parts by weight are 10-50 part and 5-10 part.
The present invention is based on the effect design of enzyme natural disposition nitric oxide in cardiovascular system, main component citrulling is in vivo by citrulling approach synthesis L-arginine, i.e. citrulling/L-arginine circulation approach, when L-arginine and citrulling act synergistically, nitric oxide production generation increases.This citrulling L-arginine recirculation approach substantially increases the nitric oxide production level of body.
Vitamin C is as antioxidant important in body; can oxidation in antagonism disease forming process; this oxidation can make nitric oxide lose activity; reduce body nitric oxide level; and destroy endothelial cell; add vitamin C and can stop oxidizing process, promote endothelial cell reparation, and the nitric oxide in protective.
There is Endothelium Dependent Vasodilatation in hyperpietic, and with blood vessel endothelium synthesize discharge nitric oxide production minimizing, active oxygen increase relevant.Nitric oxide reduces and active oxygen increases and plays a significant role in hypertensive vascular endothelium-dependent dilation function is impaired.Nitric oxide has vasodilator, suppresses smooth muscle cell proliferation and platelet aggregation, minimizing leukocyte, alleviates the effect such as endothelial cell damage, the atherosis formation of prevention of arterial.
Nitric oxide effectively can suppress the synthesis of low-density lipoprotein, make low-density lipoprotein in blood in a short time quantity reduce, make the cholesterol in blood, triglyceride also reduce thereupon.In addition, nitric oxide can promote the synthesis of HDL, the cholesterol triglyceride in blood is transported away rapidly, reaches the object of lipopenicillinase.
Vascular lesion caused by diabetes, main and metabolism obstacles of blood glucose and general glycosylation, lipidosis etc. are closely related.Current Most scholars think diabetic angiopathy and Endothelial dysfunction closely related, nitric oxide plays a very important role wherein.And many scholars find that the vascular endothelial cell of diabetes rat synthesizes nitric oxide production ability and declines.
The composition of the high patient health of conditioning three provided by the invention, also comprise conventional pharmaceutical adjuvants, described conventional pharmaceutical adjuvants comprises: malic acid, maltodextrin, sweet mellow wine and essence.In addition, the composition of the high patient health of conditioning three provided by the invention is the formulation being easy to take, absorb and carry, and the formulation of said composition is effervescent tablet, buccal tablet, granule, capsule or oral liquid, preferably, the formulation of said composition is effervescent tablet or buccal tablet.
It should be noted that, above-mentioned conventional pharmaceutical adjuvants can according to the composition of the high patient health of above-mentioned conditioning three the formulation selected and selecting.In addition, the composition of the high patient health of this conditioning three is the formulation being easy to take, absorb and carry, preferably, said composition is effervescent tablet or buccal tablet, but be not limited to effervescent tablet and buccal tablet, can be other formulations existing in prior art, as long as can be easy to take, absorb and carry, as pulvis, granule, oral liquid, capsule etc.
The formulation of above-mentioned composition is effervescent tablet, comprise the component of following parts by weight: the citrulling of 25-30 part, the malic acid of 7-10 part, the vitamin C of 5-10 part, the maltodextrin of 8-12 part, the sweet mellow wine of 10-15 part, the citric acid of 10-15 part, the sodium acid carbonate of 10-15 part, the sweetener of 0.1-0.5 part, the colouring agent of 0.1-1 part, the essence of 0.2 part, the PVP of the lubricant of 0.5 part and 0.5 part.
The formulation of above-mentioned composition is buccal tablet, comprise the component of following parts by weight: the citrulling of 10-30 part, the malic acid of 10-20 part, the vitamin C of 5-10 part, the maltodextrin of 10-20 part, the sweet mellow wine of 10-20 part, the soluble starch of 20-40 part, the essence of 0.2 part and the dolomol of 0.3-0.7 part.
Fig. 1 shows the schematic flow sheet of the preparation method of the composition of the high patient health of conditioning three that the embodiment of the present invention provides.With reference to Fig. 1, the present invention provides a kind of preparation method preparing the composition of the high patient health of above-mentioned conditioning three on the other hand, comprises the following steps:
(1) feeding: take raw material and pharmaceutic adjuvant;
(2) pulverize: the raw material beyond removing protein sugar, essence, lubricant or dolomol and pharmaceutic adjuvant are pulverized for 80-200 order fine powder;
(3) granulate: after above-mentioned fine powder is mixed, adopt wet granulation, 40-60 DEG C of dry 0.5-1.5 hour, cross the whole grain of 16-20 mesh sieve;
(4) finished product is obtained: added proteins sugar, essence, lubricant or dolomol mix rear compressing tablet, obtain above-mentioned nutritious supplementary pharmaceutical.
Preferably, above-mentioned wet granulation is spray PVP, and make wetting agent with the ethanol of 95%, but binder is not limited to PVP, wetting agent be not limited to 95% ethanol, can be the binder and wetting agent that in prior art, existing wet granulation is used, as water, starch slurry etc., only otherwise affect the composition of the high patient health of conditioning three provided by the invention effect, contribute to its preparation and its disintegration in water.
The formulation of above-mentioned composition is the preparation method of effervescent tablet: the above raw material outside removing protein sugar, essence, lubricant and pharmaceutic adjuvant are all pulverized as 80-120 order fine powder, mix, adopt wet granulation, 40-50 DEG C of dry 0.5-1.5 hour, cross the whole grain of 16-20 mesh sieve, additional essence, protein sugar, mix lubricant be rear compressing tablet evenly.
The formulation of above-mentioned composition is the preparation method of buccal tablet: pulverize as 100-200 order fine powder by the above raw material outside removing protein sugar, essence, dolomol, mix, adopt wet granulation, 50-60 DEG C of dry 0.5-1.5 hour, cross the whole grain of 20 mesh sieve, additional essence, protein sugar, dolomol mix rear compressing tablet.
It should be noted that, above-mentioned tableting processes adopts tablet press machine to be existing medicament tablet press machine in prior art, and above-mentioned crushing process adopts pulverizer to be existing high speed disintegrator in prior art.
Another aspect of the invention provides the application of composition in the nutritious supplementary pharmaceutical preparing the high patient health of comprehensively regulating three of the high patient health of described conditioning three.
Specific embodiment is implemented under premised on technical solution of the present invention, give detailed embodiment and concrete operating process, but protection scope of the present invention is not limited to following specific embodiment.In following specific embodiment, method therefor is conventional method if no special instructions.
Specific embodiment 1:
With parts by weight, unit is kilogram, takes citrulling 37 parts respectively, malic acid 8 parts, vitamin C 7 parts, maltodextrin 10 parts, 11 parts, sweet mellow wine, citric acid 12 parts, sodium acid carbonate 12 parts, sweetener 0.2, colouring agent 0.5 part, 0.2 part, essence, lubricant 0.5 part, PVP 0.5 part.
Citrulling, malic acid, vitamin C, maltodextrin, sweet mellow wine, citric acid, sodium acid carbonate, flavor enhancement, colouring agent are pulverized with high speed disintegrator respectively, fineness is made to reach 100 orders, mix by weight, spray PVP 95% ethanol makes it soak, granulate, 45 DEG C of dry 45-60 minute, cross the whole grain of 20 mesh sieve, and additional essence, mix lubricant be rear compressing tablet evenly.
Make the tablet of 4.0g/ sheet.
Usage and dosage: get this product and put into 30-40 DEG C of warm water, rapid disintegration and thawing, complete to disintegration and thawing, can take.
This product is taken before can sleeping every day, every day 1 time, each 1.
Disintegration time limited checks: (Chinese Pharmacopoeia 2010 editions)
Get effervescent tablet 6, put in 250ml beaker, in beaker, fill 200ml water, water temperature is 15-25 DEG C, has numerous air-bubble to release, when the gas around tablet or fragment stops overflowing, tablet should be dissolved or dispersed in water, left without the particle assembled, each all disintegration in 3-5 minute.
Specific embodiment 2:
With parts by weight, unit is kilogram, takes citrulling 22 parts respectively, malic acid 17 parts, vitamin C 7 parts, maltodextrin 16 parts, 11 parts, sweet mellow wine, soluble starch 32 parts, 0.2 part, essence, dolomol 0.5 part.
Citrulling, malic acid, vitamin C, maltodextrin, sweet mellow wine, soluble starch are pulverized with high speed disintegrator respectively, fineness is made to reach 200 orders, mix by weight, spray PVP 95% ethanol makes it soak, granulate, 55 DEG C of dry 45-60 minute, cross the whole grain of 20 mesh sieve, additional essence, dolomol mix rear compressing tablet.
Make the tablet of 1.0g/ sheet.
Usage and dosage: get this product and directly put into mouth containing clothes.
This product every day each 1 time sooner or later, morning and respectively take 2-4 sheet before sleeping.
Disintegration time limited checks: (Chinese Pharmacopoeia 2010 editions)
Adopt lift disintegration tester, regulate water temperature 37 ± 1 DEG C, get buccal tablet 6, put in the glass tube of hanging basket, start automatic disintegration tester and check, each all whole disintegration or dissolve in 10-15 minute.
According to the nutritious supplementary pharmaceutical of the high patient health of comprehensively regulating three prepared by the composition of the high patient health of conditioning three provided by the invention, its taking dose has two kinds of methods: method one, once a day, take 1 effervescent tablet (following effervescent tablet is the tablet described in above-mentioned specific embodiment 1) before sleeping; Method two, every day twice, morning and respectively take 2-4 sheet buccal tablet (following buccal tablet is the tablet described in above-mentioned specific embodiment 2) before sleeping.
Take effect observation:
(1) Lee hyperpietic, 42 years old, blood pressure 163/94mmHg, take this nutritional supplementation effervescent tablet after two weeks, blood pressure dropped to 120/80mmHg, and keeps stable.
(2) sleep bad, that the state of mind is not good Wang, 43 years old, because operating pressure is large, evening difficulty falling asleep, always want spended time to adjust morning, take this nutritious supplementary pharmaceutical buccal tablet after 10-15 days, fall asleep very fast, do not wake up all night, be not dizzy after getting up, but it is conscious, in high mood, energetic.
(3) Lee diabetic, 75 years old, diabetes were found before 6 years, take diabetes pill, Metformin Extended-release Tablets etc. always, after with slight complication diabetes, change and take this nutritious supplementary pharmaceutical buccal tablet after three weeks, all maintain in normal range (NR) with postprandial blood sugar before the meal, complication toe symptom of festering also makes moderate progress, and this improvement is continuation.
(4) hyperlipemic patients Zhang, 62 years old, detect total plasma cholesterol 6.2mmol/L, plasma triglyceride 2.4mmol/L, took this nutritional supplementation effervescent tablet after one month, detected total plasma cholesterol 5.2mmol/L, plasma triglyceride 1.7mmol/L.
Separately attachedly take effect in more detail, refer to table 1.
The nutritious supplementary pharmaceutical of the high patient health of comprehensively regulating three that table 1 is prepared according to the composition of the high patient health of conditioning three provided by the invention take effect
The foregoing is only the preferred embodiments of the present invention, be not limited to the present invention, for a person skilled in the art, the present invention can have various modifications and variations.Within the spirit and principles in the present invention all, any amendment done, equivalent replacement, improvement etc., all should be included within protection scope of the present invention.
Claims (9)
1. nurse one's health the compositions of three high patient healths, it is characterized in that, comprise the vitamin C of citrulling that parts by weight are 10-50 part and 5-10 part.
2. the composition of the high patient health of conditioning three according to claim 1, it is characterized in that, also comprise conventional pharmaceutical adjuvants, described conventional pharmaceutical adjuvants comprises: malic acid, maltodextrin, sweet mellow wine and essence.
3. the composition of the high patient health of conditioning three according to claim 2, is characterized in that, described composition is the formulation being easy to take, absorb and carry.
4. the composition of the high patient health of conditioning three according to claim 3, is characterized in that, the formulation of described composition is effervescent tablet, buccal tablet, granule, capsule or oral liquid.
5. the composition of the high patient health of conditioning three according to claim 4, is characterized in that, the formulation of described composition is effervescent tablet, comprise the component of following parts by weight: the citrulling of 25-30 part, the malic acid of 7-10 part, the vitamin C of 5-10 part, the maltodextrin of 8-12 part, the sweet mellow wine of 10-15 part, the citric acid of 10-15 part, the sodium acid carbonate of 10-15 part, the sweetener of 0.1-0.5 part, the colouring agent of 0.1-1 part, the essence of 0.2 part, the PVP of the lubricant of 0.5 part and 0.5 part.
6. the composition of the high patient health of conditioning three according to claim 4, it is characterized in that, the formulation of described composition is buccal tablet, comprise the component of following parts by weight: the citrulling of 10-30 part, the malic acid of 10-20 part, the vitamin C of 5-10 part, the maltodextrin of 10-20 part, the sweet mellow wine of 10-20 part, the soluble starch of 20-40 part, the essence of 0.2 part and the dolomol of 0.3-0.7 part.
7. prepare a preparation method for the composition according to the high patient health of conditioning three described in claim 5 or 6, it is characterized in that, comprise the following steps:
(1) feeding: take raw material and pharmaceutic adjuvant;
(2) pulverize: the raw material beyond removing protein sugar, essence, lubricant or dolomol and pharmaceutic adjuvant are pulverized for 80-200 order fine powder;
(3) granulate: after described fine powder is mixed, adopt wet granulation, 40-60 DEG C of dry 0.5-1.5 hour, cross the whole grain of 16-20 mesh sieve;
(4) finished product is obtained: added proteins sugar, essence, lubricant or dolomol mix rear compressing tablet, obtain described composition.
8. preparation method according to claim 7, is characterized in that, described wet granulation is spray PVP, and makes wetting agent with the ethanol of 95%.
9. the application of composition in the nutritious supplementary pharmaceutical preparing the high patient health of comprehensively regulating three of the high patient health of conditioning three according to any one of claim 1 to 6.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410566521.3A CN104256623A (en) | 2014-10-22 | 2014-10-22 | Composition for conditioning health of patient suffering from hypertension, hyperlipidemia and hyperglycemia, and preparation method and application of composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410566521.3A CN104256623A (en) | 2014-10-22 | 2014-10-22 | Composition for conditioning health of patient suffering from hypertension, hyperlipidemia and hyperglycemia, and preparation method and application of composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104256623A true CN104256623A (en) | 2015-01-07 |
Family
ID=52148308
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410566521.3A Pending CN104256623A (en) | 2014-10-22 | 2014-10-22 | Composition for conditioning health of patient suffering from hypertension, hyperlipidemia and hyperglycemia, and preparation method and application of composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104256623A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105924371A (en) * | 2016-04-28 | 2016-09-07 | 石河子开发区石大合旭科技开发有限公司 | Extraction method of L-citrulline in seed melon, and preparation method of effervescent tablet |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR6718M (en) * | 1967-04-21 | 1969-02-17 | ||
| CN101332190A (en) * | 2007-06-25 | 2008-12-31 | 北京健健康康生物技术有限公司 | Sugar-free type citrulline effervescence tablet and preparation method thereof |
| CN101332184A (en) * | 2007-06-25 | 2008-12-31 | 北京健健康康生物技术有限公司 | Sugar-free type citrulline mouth spray and preparation method thereof |
| CN101589818A (en) * | 2008-05-30 | 2009-12-02 | 北京健健康康生物技术有限公司 | A kind of sugar-free citrulline coffee tablet and preparation method thereof |
| CN101880245A (en) * | 2010-04-27 | 2010-11-10 | 南京泽朗农业发展有限公司 | Method for purifying citrulline from watermelon |
| CN102652743A (en) * | 2011-03-04 | 2012-09-05 | 林飞 | Prescription for promoting human body to generate nitric oxide |
| US20130071371A1 (en) * | 2009-06-15 | 2013-03-21 | Neogenis Labs, Inc. | Method of Producing Physiological and Therapeutic Levels of Nitric Oxide Through an Oral Delivery System |
| CN103006730A (en) * | 2012-12-31 | 2013-04-03 | 丁家宜 | Composition containing arginine and panax notoginseng extract for promoting nitric oxide generation and preventing and protecting cardiovascular disease |
-
2014
- 2014-10-22 CN CN201410566521.3A patent/CN104256623A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR6718M (en) * | 1967-04-21 | 1969-02-17 | ||
| CN101332190A (en) * | 2007-06-25 | 2008-12-31 | 北京健健康康生物技术有限公司 | Sugar-free type citrulline effervescence tablet and preparation method thereof |
| CN101332184A (en) * | 2007-06-25 | 2008-12-31 | 北京健健康康生物技术有限公司 | Sugar-free type citrulline mouth spray and preparation method thereof |
| CN101589818A (en) * | 2008-05-30 | 2009-12-02 | 北京健健康康生物技术有限公司 | A kind of sugar-free citrulline coffee tablet and preparation method thereof |
| US20130071371A1 (en) * | 2009-06-15 | 2013-03-21 | Neogenis Labs, Inc. | Method of Producing Physiological and Therapeutic Levels of Nitric Oxide Through an Oral Delivery System |
| CN101880245A (en) * | 2010-04-27 | 2010-11-10 | 南京泽朗农业发展有限公司 | Method for purifying citrulline from watermelon |
| CN102652743A (en) * | 2011-03-04 | 2012-09-05 | 林飞 | Prescription for promoting human body to generate nitric oxide |
| CN103006730A (en) * | 2012-12-31 | 2013-04-03 | 丁家宜 | Composition containing arginine and panax notoginseng extract for promoting nitric oxide generation and preventing and protecting cardiovascular disease |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105924371A (en) * | 2016-04-28 | 2016-09-07 | 石河子开发区石大合旭科技开发有限公司 | Extraction method of L-citrulline in seed melon, and preparation method of effervescent tablet |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2016173509A1 (en) | Compositions comprising cyclocarya paliurus extract and preparation method and uses thereof | |
| CN106666312A (en) | Health-care food for assisting blood glucose decreasing and preparation method of granule and capsule thereof | |
| CN106975069A (en) | A kind of liver protecting composition and preparation method thereof | |
| CN106038704A (en) | Composition for inhibiting food digestion and absorption as well as preparation method and application of composition | |
| CN1840166A (en) | Modern Chinese medicinal oral liquid of 'Wen Dan Tang' and preparation method thereof | |
| JP5969590B2 (en) | Drug composition for suppressing blood sugar, lipemia and body weight | |
| CN101485861B (en) | Chinese medicament preparation with sobering-up, blood fat-reducing, liver-protecting and cardio-cerebrovascular-protecting functions | |
| US20110104290A1 (en) | Compositions for reducing blood glucose level and uses thereof | |
| CN111919934A (en) | Safflower Suxin tea for reducing high blood pressure, high blood sugar and protecting cardiovascular and preparation method thereof | |
| CN110433259A (en) | It is a kind of to intervene the Chinese medicine composition of obstruction of the circulation of vital energy constitution, broken wall composition and preparation method thereof | |
| CN101199347A (en) | Pb excluding health care product and its preparation method | |
| CN105558198A (en) | Health-care tea capable of reducing blood sugar and preparation method of health-care tea | |
| CN106176953A (en) | A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja, Fructus Momordicae and Folium Mori | |
| CN106177183A (en) | A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja, green tea and Folium Mori | |
| CN108403818A (en) | A kind of composition of auxiliary hyperglycemic and application thereof | |
| CN101912487B (en) | Medicament for treating neuroendocrine disturbance, sexual function decline and skin aging | |
| CN104256623A (en) | Composition for conditioning health of patient suffering from hypertension, hyperlipidemia and hyperglycemia, and preparation method and application of composition | |
| CN107281386B (en) | Method for preparing medicine for treating hypertension by using dendrobium officinale and radish seeds and application | |
| CN104940263A (en) | Composition with functions of alleviating hangover and protecting liver and preparation method of composition | |
| CN109549206A (en) | A kind of thrombolysis and the functional food and preparation method thereof for preventing cardiovascular disease | |
| KR20180033781A (en) | Method of producing a food for preventing and improving diabetes | |
| CN103181945B (en) | The purposes of Semen Luffae | |
| CN108114268A (en) | A kind of Chinese medicine composition for reducing blood glucose, preparation and preparation method and application | |
| CN105168739A (en) | Anti-fatigue and eyesight-improving composition suitable for high blood pressure, high blood fat and high blood glucose | |
| CN104146271A (en) | Metabolism regulating and liver protecting nutritional supplement, preparation method and applications thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150107 |